Sameeha Fallatah1, Rolf Jäger1, and Xavier Golay1
1Brain Repair and Rehabilitation, UCL, Institute of Neurology, London, United Kingdom
Synopsis
Dynamic
Contrast Enhanced MRI is used to assess the integrity of the blood brain
barrier. A major difficulty for the method to be accepted in the clinics is the
variety of pharmacokinetic models used and their strong dependence on the
underlying assumptions and/or acquisition parameters. Thus the far simpler methods
based on signal intensity curve
characteristics are the most commonly used approaches in
clinical practice. In this study we compare two different pharmacokinetic models, the extended Tofts
model and Lawrence & Lee model in patients with primary brain
tumours. Background and Purposes
Dynamic Contrast Enhanced (DCE)-MRI is
used to assess the integrity of the blood brain barrier (BBB). The
clinical adoption of quantitative DCE-MRI has been slow, largely due to the
complexity of the measurements and its interpretation. A major difficulty for
the method to be accepted in the clinics is the large variety of
pharmacokinetic models used and their strong dependence on the underlying
assumptions and/or acquisition parameters. Thus the far simpler methods based
on signal intensity curve characteristics are the most commonly used approaches
in clinical practice.
Nevertheless, the most widely used quantitative model is the
extended Tofts model (ETM) . The ETM model allows the
quantification of forward volume transfer constant (Ktrans),
extravascular extracellular space volume (Ve), blood plasma volume (Vp) and the
reverse vascular transfer constant (Kep), based on a simple two-pool model. These
parameters reflect permeability as well as perfusion. On the other
hand, the Lawrence & Lee model (L&L) accounts for the small changes of
concentration in contrast agent over time, thus allows for flow (F), extraction
fraction (E) and mean capillary transit time (Tc) quantification. We aim in this study to compare the values of Ktrans,
ve, Kep and ve obtained by both models in a series of patients with primary
brain tumours.
Methods
Subjects: 27 patients, age 45
±15.4 years, 15 males and 12 females. 6 Astrocytoma WHO II,
5 Oligodendroglioma WHO II, 4 Oligoastrocytoma WHO II, 4 anaplastic
Oligodendroglioma WHO III, 2 Anaplastic oligoastrocytoma WHO III,
3 anaplastic astrocytoma WHO III, 3 GBM. All underwent DCE-MRI scanning as part of their standard clinical care. All
data were post-processed retrospectively as part of an approved audit by our
institution.
Post-processing: DCE data were post-processed twice with Olea Sphere™
software using both the ETM and L&L models. Four parametric maps were produced Ktrans, ve, vp and Kep
with each model.
Image analysis: A 20-30 mm2 ROI with the highest Ktrans value was used
then propagated to other DCE-MRI maps for both models to extract the mean parameters
(Ktrans, ve, vp and Kep).
Paired t-tests and Pearson's correlation
coefficient are used to study the relationship between all parameters given by
both DCE models.
Results
DCE parameter values produced by the two DCE
models are listed in table 1. Although
the measurements produced by the 2 models are highly correlated (table 2), the
differences were generally very large, with the exception of Ktrans in
all tumours, or for low-grade astrocytomas (LGA) in general. Parameters
produced by the L&L model are generallt higher than those produced by the
ETM model, with mean differences 0.02, 0.25, 0.31 and 0.63 for Ktrans,
Vp, Ve and Kep respectively.
Discussion and conclusion
The model
used can influence the resulting quantitative permeability parameters,
especially in lesions with high-level of leakage (HGA, HGO, LGO). However both
models have a strong linear relationship for all parameters, which means that
the parameters from each model give similar information, but on a different
scale. The reason for the lack of difference between models for LGA is likely
due to the low leakage rate in these lesions (Ktrans =0.001-0.002)
Acknowledgements
No acknowledgement found.References
1. Patlak CS etal. Journal of Cerebral
Blood Flow and Metabolism 1985;5(4):584–90.
2. Tofts PS etal. J Magn Reson
Imaging 1999;10(3):223–32.
3. Lawrence,
KS Lee T-Y. Journal of
Cerebral Blood Flow and Metabolism 1998;18(12):1378–85.
4. Buckley DL. Magn Reson Med
2002;47(3):601–6.
5. Cramer SP etal . J Cereb Blood Flow
Metab 2014;34(10):1655–65.